Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 0

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-269079

PROSPECTUS SUPPLEMENT

(To prospectus dated January 26, 2023)

<div align='center'>3,750,000 SHARES OF COMMON STOCK</div>

We have entered into an At
Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”) and Lake
Street Capital Markets, LLC (“Lake Street”) (each, an “Agent” and together, the “Agents”), relating
to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the
Sales Agreement, we may offer and sell up to 3,750,000 shares of our common stock, par value $0.0001 per share, from time to time through
or to the Agents, each acting as sales agent or principal.

Our common stock is currently
trading on The Nasdaq Capital Market under the symbol “DERM”. On August 25, 2025, the last reported sale price of our
common stock was $7.40.

We are a “smaller reporting
company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, and, as such, have elected to comply
with certain reduced public company reporting requirements.

Sales of our common stock,
if any, under this prospectus supplement and the accompanying prospectus will be made in sales deemed to be an “at the market”
equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities
Act”). The Agents are not required to sell any specific number or dollar amount of securities, but will act as sales agents using
commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between the Agents and
us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to the Agents
for sales of common stock sold pursuant to the Sales Agreement will be an amount equal to 3.0% of the gross proceeds of any shares of
common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, each of the Agents will be
deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of the Agents